MI­LAN — For­get We­govy and Zep­bound. Nev­er mind Ca­griSe­ma, and even re­ta­tru­tide. The lat­est big name in obe­si­ty is elo­raTZP. Da­ta re­vealed Wednes­day show that Lil­ly's amylin-in­cretin com­bi­na­tion de­liv­ered weight loss of up to 23.3% at about 11 months in pa­tients with both obe­si­ty and type 2 di­a­betes...